WWM
ASND icon

Whalen Wealth Management’s Ascendis Pharma A/S ASND Stock Holding History

Whalen Wealth Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$427K Buy
+1,867
New +$419K 0.23% 112
2025
Q4 		– Sell
-4,620
Closed -$919K – 192
2025
Q3 		$919K Buy
+4,620
New +$862K 0.54% 44

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Whalen Wealth Management's ASND Position: Q1 2026 in Review

Whalen Wealth Management opened a new position in Ascendis Pharma A/S (ASND) in Q1 2026: 1,867 shares worth $427K. The stake represents 0.23% of the portfolio and ranks #112 among its holdings. This is a return to the name: Whalen Wealth Management previously reported a position in ASND as recently as Q3 2025.

Whalen Wealth Management first reported a position in ASND in Q3 2025 and has held it in 2 quarters since. The position peaked at $919K in Q3 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • Whalen Wealth Management held 1,867 shares of Ascendis Pharma A/S worth $427K as of Q1 2026.
  • Ascendis Pharma A/S was a new Whalen Wealth Management position in Q1 2026.
  • Ascendis Pharma A/S made up 0.23% of Whalen Wealth Management's portfolio in Q1 2026, its #112 holding.
  • Whalen Wealth Management first reported a position in Ascendis Pharma A/S in Q3 2025 and has held it in 2 quarters since.
  • Whalen Wealth Management's Ascendis Pharma A/S position peaked at $919K in Q3 2025.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Whalen Wealth Management's 13F filing for Q1 2026, filed 13 Apr 2026.